CR9989A - Composición farmacéutica que comprende al menos un medicamento contra el cáncer y al menos un polímero - Google Patents

Composición farmacéutica que comprende al menos un medicamento contra el cáncer y al menos un polímero

Info

Publication number
CR9989A
CR9989A CR9989A CR9989A CR9989A CR 9989 A CR9989 A CR 9989A CR 9989 A CR9989 A CR 9989A CR 9989 A CR9989 A CR 9989A CR 9989 A CR9989 A CR 9989A
Authority
CR
Costa Rica
Prior art keywords
medicinal
polymer
pharmaceutical composition
methods
against cancer
Prior art date
Application number
CR9989A
Other languages
English (en)
Spanish (es)
Inventor
Singh Amarjit
Singh Sarbjit
K Gupta Ajay
M Kulkarni Mangesh
Original Assignee
Panacea Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Biotec Ltd filed Critical Panacea Biotec Ltd
Publication of CR9989A publication Critical patent/CR9989A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CR9989A 2005-10-21 2008-05-20 Composición farmacéutica que comprende al menos un medicamento contra el cáncer y al menos un polímero CR9989A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1327MU2005 2005-10-21
IN1081MU2006 2006-07-10

Publications (1)

Publication Number Publication Date
CR9989A true CR9989A (es) 2008-07-18

Family

ID=38163340

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9989A CR9989A (es) 2005-10-21 2008-05-20 Composición farmacéutica que comprende al menos un medicamento contra el cáncer y al menos un polímero

Country Status (13)

Country Link
US (1) US20100166872A1 (enExample)
EP (1) EP1962906A4 (enExample)
JP (1) JP2009512682A (enExample)
AR (1) AR058130A1 (enExample)
AU (1) AU2006324872B2 (enExample)
BR (1) BRPI0617663A2 (enExample)
CA (1) CA2626016A1 (enExample)
CR (1) CR9989A (enExample)
EA (1) EA015781B1 (enExample)
IL (1) IL190882A0 (enExample)
MA (1) MA29946B1 (enExample)
RS (1) RS20080167A (enExample)
WO (1) WO2007069272A2 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2853264A1 (en) * 2007-12-24 2015-04-01 Sun Pharma Advanced Research Company Limited Nanodispersion
US8871276B2 (en) 2008-02-11 2014-10-28 Technion Research And Development Foundation Ltd. Beta-casein assemblies for mucosal delivery of therapeutic bioactive agents
US20110045092A1 (en) * 2008-02-11 2011-02-24 Livney Yoav D Casein particles encapsulating therapeutically active agents and uses thereof
WO2009101613A1 (en) 2008-02-11 2009-08-20 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Beta-casein assemblies for mucosal delivery of therapeutic bioactive agents
WO2009101612A2 (en) 2008-02-11 2009-08-20 Technion Research And Development Foundation Ltd. Beta-casein assemblies for enrichment of food and beverages and methods of preparation thereof
GB0818747D0 (en) * 2008-10-13 2008-11-19 Univ Nottingham Biocompatible responsive materials
EP2266546A1 (en) 2009-06-08 2010-12-29 Advancell Advanced in Vitro Cell Technologies,S.A. Process for the preparation of colloidal systems for the delivery of active compounds
EP2442805A4 (en) 2009-06-19 2012-11-21 Sun Pharma Advanced Res Co Ltd NANODISPERSION OF A MEDICINE AND METHOD FOR PREPARING THE SAME
WO2011017835A1 (en) * 2009-08-11 2011-02-17 Nanjing University Preparation method of protein or peptide nanoparticles for in vivo drug delivery by unfolding and refolding
EP2481396A4 (en) * 2009-09-21 2014-03-05 Jw Pharmaceutical Corp OXALIPLATIN NANOPARTICLES AND MANUFACTURING METHOD THEREFOR
SG10201503234SA (en) 2010-05-03 2015-06-29 Teikoku Pharma Usa Inc Non-Aqueous Taxane Pro-Emulsion Formulations and Methods of Making and Using the Same
BR112012030641B8 (pt) * 2010-06-01 2022-06-14 Geistlich Pharma Ag Usos e composições para terapia farmacêutica oral
WO2012058462A2 (en) * 2010-10-29 2012-05-03 Isis Pharmaceuticals, Inc. Combination therapy for the treatment of cancer
JP6035633B2 (ja) * 2010-12-02 2016-11-30 グリーンマーク バイオメディカル インコーポレイテッドＧｒｅｅｎＭａｒｋ Ｂｉｏｍｅｄｉｃａｌ， Ｉｎｃ． アプタマーバイオコンジュゲート薬物送達システム
US20150037252A1 (en) 2011-04-20 2015-02-05 The University Of Sydney Method for the Treatment of a Solid Tumour
CN103635179B (zh) 2011-04-28 2017-12-29 普拉福姆五金器具第二有限公司 亲脂性药剂的改进的胃肠外制剂以及制备和使用其的方法
WO2013124867A1 (en) * 2012-02-21 2013-08-29 Amrita Vishwa Vidyapeetham University Polymer - polymer or polymer - protein core - shell nano medicine loaded with multiple drug molecules
EP2872161B1 (en) 2012-06-26 2020-12-16 Del Mar Pharmaceuticals Dianhydrogalactitol for use in treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
US10143700B2 (en) 2013-02-19 2018-12-04 Amrita Vishwa Vidyapeetham Nanoparticle formulations for delivering multiple therapeutic agents
AU2014251038A1 (en) 2013-04-08 2015-11-26 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
PT3311845T (pt) 2013-09-16 2020-04-02 Astrazeneca Ab Nanopartículas poliméricas terapêuticas e métodos para fabrico e uso das mesmas
KR20150047336A (ko) 2013-10-24 2015-05-04 삼성전자주식회사 나노입자, 이를 제조하는 방법, 및 이의 용도
HUP1300646A2 (en) 2013-11-12 2015-05-28 Druggability Technologies Ip Holdco Jersey Ltd Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
CN103739672B (zh) * 2013-12-31 2015-06-10 威特曼生物科技（南京）有限公司 一种聚乙二醇修饰的抑制vegfr2酪氨酸激酶多肽及其应用
RU2591819C2 (ru) * 2014-03-03 2016-07-20 Закрытое акционерное общество "СКАЙ ЛТД" Способ получения фолликулярного белкового препарата и препарат, полученный данным способом
TWI790191B (zh) 2015-02-01 2023-01-21 美商錫羅斯製藥公司 用於病患口服之含砷高表面積冷凍乾燥組合物
CN107530291A (zh) 2015-03-03 2018-01-02 奎尔波特股份有限公司 双重负载的脂质体药物制剂
EP3265059A4 (en) 2015-03-03 2018-08-29 Cureport Inc. Combination liposomal pharmaceutical formulations
CN106137969B (zh) * 2015-04-03 2020-05-15 四川科伦药物研究院有限公司 多西他赛白蛋白纳米粒药物组合物及其制备方法及应用
IL285928B2 (en) 2016-05-06 2025-06-01 Eagle Pharmaceuticals Inc Fulvestrant formulations and methods of their use
WO2018200393A1 (en) * 2017-04-24 2018-11-01 Zy Therapeutics Inc. Pharmaceutical composition for in vivo delivery, method of preparation of a substantially waterinsoluble pharmacologically active agent
WO2019028457A2 (en) * 2017-08-04 2019-02-07 University Of Houston System FORMULATION OF NANOSUSPENSION OF DIETHYLSTILBESTROL INJECTABLE
CA3090303A1 (en) 2018-03-28 2019-10-03 Greenmark Biomedical Inc. Phosphate crosslinked starch nanoparticle and dental treatments
CN112804878A (zh) 2018-07-31 2021-05-14 微生物公司 铋-硫醇组合物和使用方法
WO2020028561A1 (en) 2018-07-31 2020-02-06 Microbion Corporation Bismuth-thiol compositions and methods for treating wounds
FR3087650B1 (fr) * 2018-10-31 2021-01-29 Bio Even Flavine adenine dinucleotide (fad) pour son utilisation pour la prevention et/ou le traitement de cancer
CN114767879A (zh) * 2022-06-02 2022-07-22 平顶山学院 一种多西紫杉醇恶性肿瘤靶向微球及其制备方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2634397B2 (fr) * 1986-12-31 1991-04-19 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une proteine sous forme de nanoparticules
US5766635A (en) * 1991-06-28 1998-06-16 Rhone-Poulenc Rorer S.A. Process for preparing nanoparticles
WO1994026254A1 (en) * 1993-05-17 1994-11-24 The Liposome Company, Inc. Incorporation of taxol into liposomes and gels
DK1023050T3 (da) * 1997-06-27 2013-10-14 Abraxis Bioscience Llc Nye formuleringer af farmakologiske midler, fremgangsmåder til fremstillingen deraf og fremgangsmåder til anvendelsen deraf
HK1045646A1 (zh) * 1999-05-21 2002-12-06 Abraxis Bioscience, Llc 蛋白質穩定化的藥理學活性劑，其製備方法及其使用方法
CA2395132A1 (en) * 2000-01-05 2001-07-12 Imarx Therapeutics, Inc. Pharmaceutical formulations for the delivery of drugs having low aqueous solubility
ITMI20001107A1 (it) * 2000-05-18 2001-11-18 Acs Dobfar Spa Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel
CA2505520C (en) * 2002-11-06 2012-07-17 Azaya Therapeutics, Inc. Protein-stabilized liposomal formulations of pharmaceutical agents
WO2004052401A2 (en) * 2002-12-09 2004-06-24 American Bioscience, Inc. Compositions and methods of delivery of pharmacological agents

Also Published As

Publication number Publication date
EA015781B1 (ru) 2011-12-30
WO2007069272A2 (en) 2007-06-21
MA29946B1 (fr) 2008-11-03
EP1962906A2 (en) 2008-09-03
IL190882A0 (en) 2008-11-03
AR058130A1 (es) 2008-01-23
JP2009512682A (ja) 2009-03-26
EP1962906A4 (en) 2009-11-18
CA2626016A1 (en) 2007-06-21
WO2007069272A3 (en) 2007-08-23
BRPI0617663A2 (pt) 2011-08-02
US20100166872A1 (en) 2010-07-01
AU2006324872B2 (en) 2012-03-08
EA200801132A1 (ru) 2009-02-27
RS20080167A (sr) 2009-07-15
AU2006324872A1 (en) 2007-06-21

Similar Documents

Publication Publication Date Title
CR9989A (es) Composición farmacéutica que comprende al menos un medicamento contra el cáncer y al menos un polímero
BRPI0806863B8 (pt) uso de um éster de forbol na preparação de um medicamento para prevenção ou tratamento de uma infecção por hiv
MX383835B (es) Uso de cannabidiol en el tratamiento del complejo de escleroris tuberosa.
CO6670567A2 (es) Métodos de tratamiento contra el cáncer pancreático
BRPI0809164B8 (pt) Composição para administração tópica e composição farmacêutica compreendendo a referida composição
AR073123A1 (es) Composicion farmaceutica que comprende un taxano sustancialmente amorfo para utilizarse en el tratamiento de la enfermedad neoplasica
MX359413B (es) Metodos de tratamiento de carcinoma hepatocelular.
MX380318B (es) Nanoparticula que comprende rapamicina y albumina como agente anticancer.
BR112014011841A2 (pt) material de entrega de fármacos hidrofóbicos, método para a produção do mesmo e métodos para a entrega de uma composição de entrega de fármacos
CL2008002224A1 (es) Composicion farmaceutica que comprende a) un compuesto seleccionado entre paclitaxel, docetaxel, ispinesib, tiazoloquinolina, entre otro, y b) compuestos inhibidores de aurora quinasa seleccionados entre derivados de imidazopirazina; uso de combinacion y de la composicion para tratar el cancer.
MX2011011514A (es) Formulaciones de canabidiol y metodos para utilizarlas.
CO6311008A2 (es) Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+
SV2010003451A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
EP3501546A3 (de) Cystein-wirkstoff konjugate und ihre verwendung
MX2010005931A (es) Profarmacos de tetrahidrocanabinol, composiciones que comprenden profarmacos de tetrahidrocanabinol y metodos para utilizar los mismos.
GT200900175A (es) Derivados de ester y amida de indazolilo para el tratamiento de enfermedades mediadas por un receptor de glucocorticoides
CO6311006A2 (es) Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+ efectiva a dosis altas
BRPI0714553B8 (pt) derivados de camptotecina, processo para preparação dos mesmos, composição farmacêutica e seu uso
DOP2006000057A (es) Composición farmaceútica para el tratamiento del cáncer
CO6382089A2 (es) Compuestos,composiciones y metodos para el tratamiento de enfermadades causadas por un b-amiloide y sinucleinopatias
GT201400059A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, proceidmientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparacion de medicamentos
ECSP088745A (es) Derivados sustituidos de cromanol y su uso
BR112012023407A2 (pt) composição em pó farmacêutica para instalação, e, processo para a preparação da mesma.
BRPI0908194B8 (pt) Uso de uma anexina a5 recombinante, e stent de eluição de fármaco
ECSP088408A (es) Composiciones farmacéuticas que comprenden combinaciones de analgésicos y anticonvulsivantes para el tratamiento del dolor agudo y crónico